Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies

Nektar (NKTR) Therapeutics showcased data in two presentations at the 2026 American Academy of Dermatology, AAD, Annual Meeting taking place in Denver, CO. At AAD 2026, data from the global Phase 2b Rezolve-AD study in 393 patients with moderate-to-severe atopic dermatitis were presented. Patient randomization was stratified based on baseline disease severity measured by vIGA-AD and geographic region. As presented at AAD, patients in the Phase 2b REZOLVE-AD study demonstrated consistent reduction in mean Eczema Area and Severity Index, EASI, scores over the 16-week induction period as compared to placebo regardless of baseline disease severity as measured by baseline vIGA-AD scores of 3 or 4. During the 16-week induction period, patients also achieved comparable EASI-75 and EASI-90 response. These disease improvement metrics were also comparable by geographic region.